RBC Life Sciences, Inc. Reports 16% Second Quarter Sales Growth

IRVING, Texas, Aug. 3 /PRNewswire-FirstCall/ -- (RBC Life Sciences: OTC Bulletin Board: RBCL) -- RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, today reported company-wide net sales of $7.8 million for the second quarter ended June 30, 2010, compared to net sales of $6.8 million for the same period during 2009, an increase of 16%. Net sales for the six months ended June 30, 2010 also increased 16% to $14.8 million compared to net sales of $12.8 million during the same period in 2009.

For the second quarter of 2010, the Company reported net earnings of $172,000, or $0.01 per share, compared to net earnings of $277,000, or $0.01 per share, during the same quarter in 2009. Net earnings for the six months ended June 30, 2010 were $383,000, or $0.02 per share, compared to $106,000, or $0.00 per share, during the same period in 2009.

"We are pleased to report year over year sales growth in both of our industry segments as well as significant improvement in earnings during the first six months of 2010," said RBC Life Sciences President and CEO, Clinton H. Howard. "We are particularly pleased with continued recovery of our international licensee business after the challenges we faced in that market last year."

Net sales to licensees, which represent 59% of consolidated net sales, increased 28% during the first six months of 2010 over the comparable period in 2009.

About RBC Life Sciences
Through wholly owned subsidiaries,RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products under its RBC Life brand to a growing population of consumers seeking wellness and a healthy lifestyle. Through its wholly owned subsidiary, MPM Medical, the Company also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the company's Web site at www.rbclifesciences.com.

The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.

RBC Life Sciences, Inc.

Summary Results of Operations

(in thousands, except per share data)

(unaudited)











Quarters Ended June 30,




2010



2009








Net sales

$

7,838


$

6,759

Gross profit


4,182



3,521

Operating profit


357



508

Earnings before income taxes


318



466

Provision for income taxes


146



189

Net earnings


172



277








Earnings per share basic and diluted

$

0.01


$

0.01







Weighted average shares outstanding basic


21,922



21,922

Weighted average shares outstanding diluted


22,387



22,477
































Six Months Ended June 30,




2010



2009








Net sales

$

14,820


$

12,775

Gross profit


7,045



6,660

Operating profit


757



347

Earnings before income taxes


679



263

Provision for income taxes


296



157

Net earnings


383



106








Earnings per share basic and diluted

$

0.02


$

0.00








Weighted average shares outstanding basic


21,922



21,920

Weighted average shares outstanding diluted


22,322



22,509


























RBC Life Sciences, Inc.

Condensed Balance Sheets

(in thousands)

(unaudited)





June 30,



December 31,




2010



2009

Assets






Cash and cash equivalents

$

3,697


$

3,972

Inventories


4,804



5,344

Other current assets


2,002



1,914


Total current assets


10,503



11,230

Other assets


7,207



7,383


Total assets

$

17,710


$

18,613








Liabilities and shareholders' equity






Accounts payable and accrued liabilities

$

2,444


$

Back to news